Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drug Safety
Published in: Drug Safety 8/2009

01-08-2009 | Original Research Article

Remedies Containing Asteraceae Extracts

A Prospective Observational Study of Prescribing Patterns and Adverse Drug Reactions in German Primary Care

Authors: Dr Elke Jeschke, Thomas Ostermann, Claudia Lüke, Manuela Tabali, Matthias Kröz, Angelina Bockelbrink, Claudia M. Witt, Stefan N. Willich, Harald Matthes

Published in: Drug Safety | Issue 8/2009

Login to get access

Abstract

Background: The use of complementary therapies by patients has increased over the past 20 years, both in terms of self-medication and physician prescriptions. Among herbal medicines, those containing extracts of Asteraceae (Compositae), such as Echinacea spp., Arnica montana, Matricaria recutita and Calendula officinalis, are especially popular in the primary-care setting. However, there remains a gap between the growing acceptance of these remedies and the lack of data on their safety.
Objective: The aim of this study was to analyse prescribing patterns and adverse drug reactions (ADRs) for Asteraceae-containing remedies in Germany.
Methods: Primary-care physicians, all of whom were members of the German National Association of Anthroposophic Physicians were invited to participate in this prospective, multicentre, observational study. During the study period (September 2004 to September 2006), all prescriptions and suspected ADRs for both conventional and complementary therapies were documented using a web-based system. The study centre monitored all ADR reports and conducted a causality assessment according to Uppsala Monitoring Centre guidelines. Relative risks (RRs) and proportional reporting ratios (PRRs) were calculated.
Results: Thirty-eight physicians, 55% of whom were general practitioners and 45% were specialists, fulfilled the technical requirements and were included in the investigation. Because documenting all ADRs (i.e. serious and non-serious) was time consuming, only a subgroup consisting of seven physicians agreed to report nonserious in addition to serious ADRs. During the study period, a total of 50 115 patients were evaluated and 344 ADRs for conventional and complementary remedies were reported. Altogether, 18 830 patients (58.0% female, 60.3% children) received 42 378 Asteraceae-containing remedies. The most frequently prescribed Asteraceae was Matricaria recutita (23%), followed by Calendula officinalis (20%) and Arnica montana (20%). No serious ADRs for Asteraceae-containing remedies were reported. In the analysis of the subgroup of seven physicians who also documented nonserious ADRs, 11 nonserious ADRs for Asteraceae-containing remedies occurred in 6961 patients, resulting in an RR of 0.13 (95% CI 0.07, 0.23). The majority of reported ADRs for Asteraceae-containing remedies were classified as uncommon. A subgroup analysis comparing phytotherapeutic and homoeopathic preparations did not reveal any relevant differences. The PRR for Asteraceae-containing remedies with respect to all other prescriptions was 1.7 (95% CI 1.0, 2.0) for the system organ class ‘skin and subcutaneous tissue disorders’ (six ADRs) and 1.0 (95% CI 0.3, 3.6) for ‘gastrointestinal disorders’ (three ADRs). Neither result was significant according to the PRR criteria developed by Evans et al.
Conclusion: This is the first study to provide a systematic overview of prescribing patterns and ADRs for Asteraceae-containing remedies in the German primary-care sector. Asteraceae-containing remedies were used frequently in this context, especially among children. Our results indicate that treatment with Asteraceae-containing remedies is not associated with a high risk of ADRs.
Literature
1.
Ross S, Simpson CR, McLay JS. Homoeopathic and herbal prescribing in general practice in Scotland. Br J Clin Pharmacol 2006; 62: 647–52PubMedCrossRef
2.
Hughes R, Ward D, Tobin AM, et al. The use of alternative medicine in pediatric patients with atopic dermatitis. Pediatr Dermatol 2007; 24: 118–20PubMedCrossRef
3.
Mullins RJ, Heddle R. Adverse reactions associated with echinacea: the Australian experience. Ann Allergy Asthma Immunol 2002; 88: 42–51PubMedCrossRef
4.
Harms H. Compositae drugs in Central Low German prescriptions from East Frisia (16th and early 17th century) [in German]. Med Monatsschr 1969; 23: 312–5PubMed
5.
Schwester T. Korbblütler. Homoeopathia viva 2005; 3(1): 1–5
6.
Weckenmann M. Entwurf einer synthetischen Betrachtung der Compositen. Beiträge zu einer Erweiterung der Heilkunst nach geisteswissenschaftlichen Erkenntnissen 1975; 28(1): 1–4
7.
Mamedov NA. Medical plants of compositae family in Karabakh. Acta Hort 1996; 79–82
8.
Barrett B, Vohmann M, Calabrese C. Echinacea for upper respiratory infection. J Fam Pract 1999; 48: 628–35PubMed
9.
Linde K, Barrett B, Wolkart K, et al. Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev 2006; (1): CD000530
10.
Ludtke R, Hacke D. On the effectiveness of the homeopathic remedy Arnica Montana [in German]. Wien Med Wochenschr 2005; 155: 482–90PubMedCrossRef
11.
Jeffrey SL, Belcher HJ. Use of Arnica to relieve pain after carpal-tunnel release surgery. Altern Ther Health Med 2002; 8: 66–8PubMed
12.
Widrig R, Suter A, Saller R, et al. Choosing between NSAID and arnica for topical treatment of hand osteoarthritis in a randomised, double-blind study. Rheumatol Int 2007; 27: 585–91PubMedCrossRef
13.
Basch E, Bent S, Foppa I, et al. Marigold (Calendula officinalis L.): an evidence-based systematic review by the Natural Standard Research Collaboration. J Herb Pharmacother 2006; 6: 135–59PubMedCrossRef
14.
15.
Paulsen E. Contact sensitization from Compositae-containing herbal remedies and cosmetics. Contact Dermatitis 2002; 47: 189–98PubMedCrossRef
16.
Jovanovic M, Poljacki M, Duran V, et al. Contact allergy to Compositae plants in patients with atopic dermatitis. Med Pregl 2004; 57: 209–18PubMedCrossRef
17.
Fuiano N, Incorvaia C, Riario-Sforza GG, et al. Anaphylaxis to honey in pollinosis to mugwort: a case report. Eur Ann Allergy Clin Immunol 2006; 38: 364–5PubMed
18.
Levenson D. Physicians should increase knowledge of herbal remedies. Rep Med Guidel Outcomes Res 2001; 12: 7–9
19.
Suchard JR, Suchard MA, Steinfeldt JL. Physician knowledge of herbal toxicities and adverse herb-drug interactions. Eur J Emerg Med 2004; 11: 193–7PubMedCrossRef
20.
Clement YN, Williams AF, Khan K, et al. A gap between acceptance and knowledge of herbal remedies by physicians: the need for educational intervention. BMC Complement Altern Med 2005 Nov 18; 5: 20PubMedCrossRef
21.
Matthes H, Tabali M, Jeschke E. Ein Pharmakovigilanzsystem für Arzneimittel der besonderen Therapierichtungen. EHK 2008; 57: 34–9CrossRef
22.
Steiner R, Wegmann I. Extending practical medicine: fundamental principles based on the science of the spirit. Bristol: Rudolf Steiner Press, 1996
23.
Jeschke E, Schad F, Pissarek J, et al. QuaDoSta-ein frei konfigurierbares System zur Unterstützung multi-zentrischer Datenerhebungen in medizinischer Versorgung und Forschung. GMS Med Inform Biom Epidemiol 2007; 3 (2): Doc10
24.
The Uppsala Monitoring Centre. Safety monitoring of medical products: guidelines for setting up and running a pharmacovigilance centre. Uppsala: The Uppsala Monitoring Centre, 2000
25.
26.
The Council for International Organizations of Medical Sciences (CIOMS). Guidelines for preparing core clinical safety information on drugs. Report of the CIOMS Working Group III and V. 2nd ed. Geneva: CIOMS, 1999
27.
SPSS Inc. SPSS 15.0 for Windows. Chicago (IL): SPSS Inc., 1989–2007
28.
Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001; 10: 483–6PubMedCrossRef
29.
Veehof LJ, Stewart RE, Meyboom-de Jong B, et al. Adverse drug reactions and polypharmacy in the elderly in general practice. Eur J Clin Pharmacol 1999; 55: 533–6PubMedCrossRef
30.
31.
Jeschke E, Luke C, Ostermann T, et al. Prescribing practices in the treatment of upper respiratory tract infections in anthroposophic medicine [in German]. Forsch Komplementarmed 2007; 14: 207–15CrossRef
32.
Schneider B, Hanisch J, Weiser M. Complementary medicine prescription patterns in Germany. Ann Pharmacother 2004; 38: 502–7PubMedCrossRef
33.
Hamre HJ, Witt CM, Glockmann A, et al. Use and safety of anthroposophic medications in chronic disease: a 2-year prospective analysis. Drug Saf 2006; 29: 1173–89PubMedCrossRef
34.
Keddie Z, Jones R. Information communications techno logy in general practice: cross-sectional survey in London. Inform Prim Care 2005; 13: 113–23PubMed
35.
Robertson J, Henry D, Dobbins T, et al. Prescribing patterns in general practice: a comparison of two data sources. Aust Fam Physician 1999; 28: 1186–90PubMed
36.
Begaud B, Martin K, Haramburu F, et al. Rates of spontaneous reporting of adverse drug reactions in France [letter]. JAMA 2002; 288: 1588PubMedCrossRef
37.
Hasford J, Goettler M, Munter KH, et al. Physicians’ knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions. J Clin Epidemiol 2002; 55: 945–50PubMedCrossRef
38.
Zhai Z, Liu Y, Wu L, et al. Enhancement of innate and adaptive immune functions by multiple Echinacea species. J Med Food 2007; 10: 423–34PubMedCrossRef
39.
Knuesel O, Weber M, Suter A. Arnica montana gel in osteoarthritis of the knee: an open, multicenter clinical trial. Adv Ther 2002; 19: 209–18PubMedCrossRef
40.
Agosti R, Duke RK, Chrubasik JE, et al. Effectiveness of Petasites hybridus preparations in the prophylaxis of migraine: a systematic review. Phytomedicine 2006; 13: 743–6PubMedCrossRef
41.
Miller AL. The etiologies, pathophysiology, and alternative/ complementary treatment of asthma. Altern Med Rev 2001; 6: 20–47PubMed
42.
Ziolo G, Samochowiec L. Study on clinical properties and mechanisms of action of Petasites in bronchial asthma and chronic obstructive bronchitis. Pharm Acta Helv 1998; 72: 378–80PubMed
43.
Noonan K, Arensman RM, Hoover JD. Herbal medication use in the pediatric surgical patient. J Pediatr Surg 2004; 39: 500–3PubMedCrossRef
44.
Alves AR, da Silva MJ. Use of phytotherapy in children up to 5 years of age in a central and peripheral area of the city of Sao Paulo [in Portuguese]. Rev Esc Enferm USP 2003; 37: 85–91PubMedCrossRef
45.
Final report on the safety assessment of Arnica montana extract and Arnica montana. Int J Toxicol 2001; 20 Suppl. 2: 1–11
46.
Reider N, Sepp N, Fritsch P, et al. Anaphylaxis to camomile: clinical features and allergen cross-reactivity. Clin Exp Allergy 2000; 30: 1436–43PubMedCrossRef
Metadata
Title
Remedies Containing Asteraceae Extracts
A Prospective Observational Study of Prescribing Patterns and Adverse Drug Reactions in German Primary Care
Authors
Dr Elke Jeschke
Thomas Ostermann
Claudia Lüke
Manuela Tabali
Matthias Kröz
Angelina Bockelbrink
Claudia M. Witt
Stefan N. Willich
Harald Matthes
Publication date
01-08-2009
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 8/2009
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200932080-00007

Other articles of this Issue 8/2009

Drug Safety 8/2009 Go to the issue

Editorial

Outliers and Patients with Adverse Drug Reactions

Original Research Article

Thiazolidinediones and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus

Original Research Article

Application of the Bow-Tie Model in Medication Safety Risk Analysis

Review Article

Serenoa repens (Saw Palmetto)

Correspondence

The Authors’ Reply

Current Opinion

Do Nanomedicines Require Novel Safety Assessments to Ensure their Safety for Long-Term Human Use?